Background Calprotectin (S100A8/S100A9), a heterodimeric EF-hand Ca 2+ binding protein, are abundant in cytosol of neutrophils and are involved in inflammatory processes and several cancerous pathogens. Objective The purpose of the present systematic review is to evaluate the pro-and anti-tumorigenic functions of calprotectin and its relation to inflammation. Materials and methods We conducted a review of studies published in the Medline (1966Medline ( -2018, Scopus (2004Scopus ( -2018, ClinicalTrials.gov (2008) and Google Scholar (2004 databases, combined with studies found in the reference lists of the included studies. Results Elevated levels of S100A8/S100A9 were detected in inflammation, neoplastic tumor cells and various human cancers. Recent data have explained that many cancers arise from sites of infection, chronic irritation, and inflammation. The inflammatory microenvironment which largely includes calprotectin, has an essential role on high producing of inflammatory factors and then on neoplastic process and metastasis. Conclusion Scientists have shown different outcomes in inflammation, malignancy and apoptosis whether the source of the aforementioned protein is extracellular or intracellular. These findings are offering new insights that anti-inflammatory therapeutic agents and anti-tumorigenic functions of calprotectin can lead to control cancer development.
Introduction
The S100s are low molecular weight proteins which represent the largest subgroup within the Ca 2+ -binding EF-hand. This superfamily comprising of more than 20 members in the human genome, it's genes cluster are located on chromosome 1q21 and similar numbers have been found in other mammalian based on genomic analysis [1] . They were first isolated originally from bovine brain tissue by Moore et al. in 1965 and represent small acidic proteins with a unique solubility in a solution of 100% saturated ammonium sulfate, which termed "S100" [2, 3] . Calprotectin, a members of S100s proteins, is a heterodimeric calcium-binding protein consisting of S100A8 and S100A9 subunits [4] . They are expressed in a wide variety of cell types and are abundant in myeloid cells such as: neutrophils, monocytes, keratinocytes and early differentiation states of macrophages. So, S100A8 and S100A9 are called myeloid-related protein and are known as: MRP-8 and MRP-14 too [5, 6] . Furthermore, S100A8 and S100A9 are denoted as Calgranulin A and Calgranulin B respectively which reflect their calcium-binding properties and highly overexpressed in granulocytes. The S100A8/S100A9 are released by activated granulocytes and act in a cytokine-like manner by binding to cell surface receptors which trigger signaling pathways involved in the inflammatory processes and play critical roles in numerous cellular processes includes cell cycle progression, cell survival, proliferation, differentiation, and cell migration. Furthermore, they exert a wide range of functions including: calcium homeostasis regulation which involved in proteins phosphorylation, cytoskeletal components rearrangement, 1 3 specific interacts with components of the cytoskeleton such as: Microtubules, Vimentin, Keratin, and Actin filaments and cell migration in a calcium-dependent manner. It is also a zinc and manganese chelator which can inhibit microbial growth and activity of zinc-dependent enzymes such as: matrix metalloproteinase [4, 7, 8] . It should be noted that in the normal conditions, the concentration of calprotectin in human serum is less than 1 µg/ml, which increase in such inflammatory disease including: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cystic fibrosis, chronic bronchitis, autoimmune disease and many types of cancers and neurodegenerative disorders such as Alzheimer. It is suggested that calprotectin can be considered as a significant marker for diagnostic purposes [9] [10] [11] [12] . The diagnosis of digestive system cancer is a major challenge for primary care. Fecal calprotectin can also be considered as a strong fecal marker in the diagnosis of various gastrointestinal disorders and cancers, especially in patients with normal colonoscopy findings [13] . The mechanism of its secretion from neutrophils is not precisely described, but it is evident that calprotectin is secreted through a Golgi-independent pathway [14, 15] .
The structure of S100A8/S100A9
Calprotectin subunits are low molecular weight proteins. The molecular masses of S100A8 and S100A9 are 10.8 and 13.2 KD which includes 93 and 114 amino acids, respectively. The structural architectures of all S100 proteins are highly conserved, Although the homology of their sequences are between 25-65% [16] . Each monomer of S100A8/ S100A9 comprises 4 α-helices (HI, HII, HIII and HIV) and 2 loops (Loop I and Loop II). Based on the first structure of these proteins, Both N and C-terminal sequences are relatively hydrophobic residues and the C-terminal tail of S100A9 is the longest one within all S100s proteins family. The S100A8 /S100A9 protein dimer interface is formed by helices, Specially HI and HIV, from both monomers which a compact four helix bundle is created (Fig. 1) . Both monomers of S100A8 and S100A9 also form stable noncovalently associated homo-dimers [17] . Tetramer formation which recently described, was made in the presence of calcium and in the absence of it, the heterodimer is the preferred form of human S100A8 and S100A9. Two isoforms of human S100A9 protein are encoded by a single copy of gene: fulllength and truncated S100A9*, which are translated from a different start site at codon 4, in comparison with the fulllength one. They have no single Cys residue, Cys3, which reduce their susceptibility to oxidation. The two isoforms are observed in human neutrophils, and the fact that each one has its own distinct functions is highly interesting [18] .
Ca binding site
The structure and function of calprotectin are determined by some metal ions such as: Ca 2+ , Zn 2+ and Mn 2+ via binding to defined motifs and specific sites, usually dimer structure of the protein. The Ca 2+ -binding EF-hand motifs are consisted of a central calcium-binding loop which flanked by two helices called helix-loop-helix motifs. Each S100A8/ S100A9 monomer is composed of two Ca 2+ -binding EFhand motifs which arranged in a back to back manner and connected by a flexible linker. So calprotectin is able to bind to four calcium ions per dimer structure and eight calcium ions per tetramer complex. The far UV CD (Circular Dichroism) spectrum of both monomers of calprotectin was carried out in the presence of calcium ions to show the changes in the secondary structures of S100A8/S100A9 [17, 19] . The results indicate a high level of α-helical content, which is a suitable index for EF-hand protein family. The CD data Fig. 1 The structure of calprotectin (S100A8/S100A9). Schematic depiction of the secondary structure of S100A8 and S100A9 proteins. Each calprotectin monomer consists of two Ca 2+ binding EF hand motifs in the N-terminal and C-terminal of sequence which are connected by a linker region (hinge region) [17] confirmed that the secondary structure of human S100A8/ A9 complex was different at concentration of 1 mM calcium ion and has a reduction in α-helix content and an increase in β-and other structures. At the C-terminal canonical EF-hand (site II), there are a Ca 2+ -binding loop between two supporting α-helices HIII and HIV which has typical 12 amino acid residues [20] . In the case of S100A8 and S100A9, the Ca 2+ -binding site includes Asp58-Glu70 and Asp67-Glu78 residues. On the other hand, the N-terminal EF-hand (site I) consists of an extended EF-hand loop which positioned between two supporting α-helices HI and HII and has 14 amino acid residues which characterized by the lower affinity towards Ca 2+ . In the case of S100A8, this area consists of Ser20-Asp33 residues and in the case of S100A9 the Ser23-Glu37 respectively [16, 21] . Ca 2+ binding modulates S100A8 and S100A9 structural conformation, thus promoting the structural changes that expose hydrophobic patches specially both α-helix HI and HIV in the N-and C-terminal, Which is important in forming the dimer structure, bind to various target proteins and improves its affinity for transition metals too [22] (Fig. 2) .
Metal binding site
The X-ray diffraction analysis of human S100A8/A9 calprotectin revealed two different putative sites which are specific for Zn 2+ -binding and have formed by highly conserved histidines and one aspartate at the interface between two monomer including S100A8 and S100A9 in the dimer structure. The first zinc-binding sites called His3Asp motif which in S100A8 is composed of two histidine residues (His83 and His87), and in S100A9 only one histidine and an aspartic acid residue (His20 and Asp30). The second Zn 2+ -binding site of calprotectin is a tetra-histidine (His4) motif which S100A8 coordinates through two histidine ligands (His17 and His27) and S100A9 through other two histidine ligands (His91 and His95) [19, 22] . Calcium, however, improves calprotectin's affinity for zinc but it is not necessary for this process and this also can occur in the absence of calcium. In addition to, the Zn 2+ -induced S100A8/A9-tetramerization was also demonstrated using biophysical methods such as MALDI-MS, ESI-MS and fluorescence spectroscopy. About another metal ion, Mn, a specific binding site has been known. Hexa-histidine (His6) motif is similar to His4 but there are two further histidine residues binding, His103 and His105 are recruited from the C-terminal end of S100A9 to enable octahedral coordination of the transition metal. Manganese is bound to calprotectin dimer at this His6 motif only in the presence of calcium [23] (Fig. 3) .
The receptors of S100A8/S100A9
It has been confirmed that S100A8/S100A9 binds to diverse cell surface proteins and activates distinct signaling pathways in various cells. S100A8/S100A9 has a high affinity for heparin sulfate proteoglycan and carboxylated N-glycans Fig. 2 Structure-based amino acid sequence alignment of S100A8 and S100A9. Mutually conserved residues are boxed. Each chain is composed of two EF-hands. EF-hand I comprises helix I (residues 4-20 in S100A8, residues 7-23 in S100A9), the non-canonical Ca 2+ -binding loop (residues 21-30 in S100A8, residues 24-33 in S100A9), and helix II (residues 31-41 in S100A8 and residues 34-44 in S100A9). EF-hand II comprises helix III (residues 51-58 in S100A8, residues 56-66 in S100A9), the canonical Ca 2+ -binding loop (residues 59-67 in S100A8, residues 67-75 in S100A9), and helix IV (residues 68-86 in S100A8 and residues 76-94 in S100A9). The two EF-hands are separated by linker regions of different lengths in both proteins (residues 42-50 in S100A8 and residues 45-55 in S100A9). The two HXXXH motifs close to the C termini of S100A8 and S100A9, which were proposed to form Zn 2+ -binding sites, are highlighted in cyan, whereas the His and Asp residues that were found here to complement these coordinating residues from the opposite chain are highlighted in yellow [22] on the surface of endothelial cells [24] . and carboxylated N-glycans on the surface of chondrocytes [25] . Attending the numerous studies in this field, calprotectin has been described as an endogenous ligand when it is secreted from activated neutrophil cells to the extracellular space. Three types of receptors have suggested for this protein which almost involved in the positive feedback mechanism of inflammation [14, 26] .
RAGE (advanced glycation end products)
The multi-ligand RAGE receptor is belonging to the immunoglobulin super family and expressed in a wide range of cells, including endothelial cells, smooth muscle cells, lymphocytes, monocytes, and neurons [27] . It's composed of three Immunoglobulin (Ig) domains (V, C1 and C2), a trans-membrane helix with a cytoplasmic tail. RAGE could be bound to various ligands and signaling molecules such as advanced glycation end product (AGE), beta amyloid, high mobility group box1 (HMGB1), S100 family protein members, the complement system members (C3a, C1q and complement receptor 3), fibrils, nucleic acids and phospholipids. RAGE was repeatedly suggested to act as a S100A8/ S100A9 receptor which offers an attractive model to represent how its associated ligands might contribute to the pathophysiology condition of disease and perturbation of cell homeostasis, cell migration and differentiation [28, 29] (Fig. 4) . Moreover, the S100B and S100A12 signaling via RAGE has been observed in a novel inflammatory axis and co-expression of several S100 proteins and RAGE has been demonstrated in prostate, breast, pancreas, and lung tumor tissues. RAGE binding to ligands can trigger multiple downstream signaling cascades including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), the Ras homologous-GTPases (Rho-GTPases), the Janus kinase/signal transducers and activators of transcription (JAK/STAT), cell division control protein 42 homolog/ Ras-related C3 botulinum toxin substrate 1 (Cdc42/Rac 1) and activation of nuclear factor κB (NF-κB) and activator protein 1 (AP-1) which leads to production of special inflammatory agents which plays a critical role in immune response, inflammation, survival and proliferation [30] [31] [32] [33] . The RAGE activation has been considered as a key event in inflammation process and the receptor-ligand interactions could be explained by a novel pro-inflammatory axis which has involved in several inflammatory diseases and various cancers [34] . Based on these facts, RAGE blockage as a promising strategy has a great role in treatment of diabetic complications, neurodegenerative disorders and various types of cancers. Efforts has been done towards RAGE as a therapeutic target involved the use of extracellular ligand binding region of RAGE (sRAGE) which impressively contend with the receptor. Studies revealed that sRAGE blockage has been beneficial in mouse models for different diseases [35] .
TLR4 (toll-like receptor 4)
TLR4, a 95 kDa type1 integral membrane protein, is a member of the toll-like receptor (TLR) family which belongs to the pattern recognition receptor (PRR) family. It is highly expressed on antigen-presenting cells of immune system such as macrophages and dendritic cells [8] . This receptor has an extracellular leucine-rich repeat (LRR) domain with a main role in ligand recognition and an intracellular toll/interleukin-1 receptor (TIR) domain which plays a major role in signal transduction. Recent investigations have been identified that S100A8/S100A9 complex as a damage-associated molecular patterns Fig. 3 a Arrangement of the two different Zn 2+ binding sites in the S100A8/S100A9 Heterodimer which consist of His3Asp tetradentate and His4 tetra-histidine. b Site 3 is a His6 hexa-histidine motif for the Mn (II)-coordinating residues and the Mn (II) ion [22, 23] (DAMPs) molecule, is an endogenous activators of TLR4. Binding of S100A8/S100A9 to TLR4, triggers a specific signaling pathway in cells which results in an autocrine positive feedback loop and an amplification of endotoxininduced up-regulation of inflammatory factor such as cytokine, chemokine and tumor necrosis factor (TNF)-α [1, 36, 37] . TLR4 signaling leads to activation of NF-kB which could motivate pro-inflammatory signals transduction which leads to activation of the innate immune system and provides tissue damage. The receptor detects molecular patterns which are associated with pathogens and leads to produce required cytokines for the improvement of innate immunity. This receptor has a great role in signal transductions which induced by lipopolysaccharide (LPS) in most gram negative bacteria [31] . TLR4 associates with myeloid differentiation factor 88 (MyD88), and this stimulates a kinase cascade resulting in the activation of MAPKs and NF-kB pathways. Furthermore investigations revealed that S100A8/ S100A9 induce translocation of adaptor protein MyD88 from the cytoplasmic space to the receptor complex in the cell membrane and make interaction with active receptor due to activation of some transcription factors such as extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), p38 and NF-kB. During TLR4 activation, the increased expression of intracellular components of the TLR4 signaling cascade were observed [38, 39] (Fig. 4) .
EMMPRIN (extracellular matrix metalloprotease inducer)
Extracellular matrix metalloprotease inducer also known as CD147 and basigin belongs to the immunoglobulin (Ig) superfamily. The human EMMPRIN receptor is a type I integral membrane receptor which contains 269 amino acids and two C2 type immunoglobulin-like domains at the N-terminal that have heavily became glycosylated in extracellular space [40] . It is expressed in wide range of cell types, including epithelial cells, endothelial cells and leukocytes and also involved in fetal development, retinal function, nervous system development, and formation of plaque in Alzheimer disease [41, 42] . EMMPRIN induces the production of cytokines and several types of Matrix metal-proteinases or MMPs which are zinc-dependent endopeptidases and play a major role in cellular process such as inflammation, cell proliferation, differentiation, migration (adhesion/dispersion), angiogenesis, apoptosis, and host defense [43] . Recent reports provide new insights into the molecular mechanism of S100A9-EMMPRIN-mediated inflammation and cancer cell metastasis interestingly [44, 45] . It is clear that S100A9 monomer, but not S100A8 monomer, has high affinity for EMMPRIN so suggested that EMMPRIN specifically binds to S100A9. Thus, the S100A8/A9 heterodimer also could bind to EMMPRIN [46, 47] . EMMPRIN is also known as a signaling receptor for cyclophilins A and B. These proteins occupy a higher percentage of the cytoplasmic proteins of Fig. 4 The activation of calprotectin's receptors which including of advanced glycation end products (RAGE), Toll-like receptor 4 (TLR4) and The extracellular matrix metalloprotease inducer (EMMPRIN), can lead to the activation of the MAPK pathways and the translocation of NF-kB from the cytosol to the nucleus, resulting in the up-regulation of genes involved in cell survival, proliferation and inflammation neutrophils and due to EMMPRIN activation, the complex is trans-located to the membrane which play essential roles in neutrophil activation. EMMPRIN and RAGE have distinct properties in S100A9-induced signal transduction [48] (Fig. 4) . Recent findings show EMMPRIN signaling cascade used the TNF-α receptor associated factor TRAF2, TRAF6 and TIRAP and finally induced tumor cells to secrete proinflammatory factors including Vascular endothelial growth factor (VEGF)-A, Transforming growth factor beta (TGF-β), and TNF-a, thereby make it easier to home to tumorspecific pre-metastatic sites. EMMPRIN is overexpressed in various cancerous cells and is associated with cancer cell malignancy [49] . As regards, EMMPRIN has a central role in matrix metalloproteinase (MMPs) stimulation which are required for tumor invasion and metastasis. The process is occurred by cell-cell and cell-matrix interactions. CD147 also could stimulate vascular endothelial growth factor (VEGF) production which results in angiogenesis. The heterophilic interactions and homo-oligomerization of CD147 receptor with other molecules including mAbs, integrins and cyclophilins still should be clarified [46, 50] .
Understanding the link between inflammation and cancer
In 1863, Virchow suggested that the origin of cancer was associated with the sites of chronic inflammation [51] . Persistent immune system activation including infection and autoimmune diseases induces chronic inflammation. Studies suggested the strong relationship between inflammation, innate immunity and cancer and it is widely accepted many malignancies are initiated by infections; however, the molecular and cellular mechanisms which can explain this relationship have remained largely unresolved [30] . Upto15% of malignant disease worldwide can be attributed to infections. The remarkable association of chronic inflammation with malignancies has been observed in colon, bladder, liver, rectal, ovarian and gastric cancers (Table 1) . DNA damage resulting from chronic inflammation has been thought to be the primary cause of cancer-inducing agents. On the other hand, it is now clear that the pro-tumor activity of inflammatory cells include environmental exposure (an environment enriched by inflammatory agents and growth factors), could certainly initiate and promote neoplasmic risk [52] . Activation of some signaling pathways in inflammatory cells induce releasing factors which is related to cellular growth, survival, angiogenesis promotion process, DNA damage-stimulating and Extracellular Matrix (ECM) remodeling which utilized to facilitate invasion mechanisms, coating tumor cells to make available receptors for distributing cells through lymph nodes and capillaries, and preventing host defense actions [53] . It is clear that cytokine's inflammatory factors such as TNF and interleukin-6 (IL-6) have mitogenic effects on inflammatory cells. Prolong inflammation condition leads to chronic inflammation and preservation of inflammatory agents and growth factors in extracellular space resulting continue to proliferating cells in microenvironments [54, 55] . The generation of reactive oxygen and nitrogen species that are produced normally by these cells could fight infection on one side, and through repeated tissue damage. Regeneration during inflammation Squamous cell carcinoma (SCC) of the bladder [73] on the other side, induces cell DNA damage in proliferating cells and makes permanent altered genome. Recent studies showed that mutations in cell cycle checkpoint, tumor suppressor genes or DNA repair genes can actually cause the formation of different cancers types. For example, p53 tumor suppressor gene mutations have been observed in various spontaneous tumors in human and is associated with chronic inflammatory disease including rheumatoid arthritis and inflammatory bowel disease [56] . On the evidence of a wide range of sources, inflammation has a significant role during neoplastic progression and in long-term use nonsteroidal anti-inflammatory drugs (NSAIDs) For example, aspirin may protect against various cancers. The best evidence to prove that NSAIDs are useful in cancer treatment is the outcomes which show these drugs reduce colon cancer risk by 40-50%, and may be preventative for lung, esophagus and stomach cancer [57, 58] . So anti-inflammatory drugs can be considered as useful options for cancer prevention and metastatic process inhibition [59, 60] .
Pro-Tumor Responses of S100A8/S100A9 and inflammation
Over the past 15 years, studies suggested that inflammation and S100A8/S100A9 were associated importantly, but the functions of S100A8/S100A9 in this context are not clear exactly. It has become increasingly evident that S100A8/ S100A9 is involved in promoting the inflammatory response in infections and autoimmune disease on one side, and was identified as a potent amplifier of inflammation in cancer and tumor invasion and metastasis on the other side [6] . calprotectin has recently been considered as a significant endogenous danger signal or DAMP and an excellent biomarker for inflammatory processes which can trigger intracellular signaling cascades in adjacent cells and leads to release of essential mediators of inflammation and launching of inflammatory processes [74, 75] . It has been shown that many of these mediators including TNF-α, interleukin (IL)-1, IL-6, chemokines, matrix metalloproteases (MMP), angiogenic factors, and anti-apoptotic protein are upregulated in stimulated cells with S100A8/A9 [52, 53, 76] . The S100A8/A9 protein increases the NF-kB-dependent transcriptional activity through binding to specific receptors on cell surface and actively participates in modulation of inflammation and immune responses which play important roles in growth and progression of neoplastic disease, as discussed previously [1, 34, 77] . Furthermore, S100A8/A9 induced cytokines and chemokines expression, in turn, stimulated granulocytes and keratinocytes to synthesize and secrete S100A8/A9. These results suggesting a positive feedback mechanism between S100A8/A9 protein and these pro-inflammatory factors [78] . Primary tumor cells also release pro-inflammatory factors such as: VEGF-A, TGF-β, and TNF-α, which lead to selective expression of chemo-attractants S100A8 and S100A9, then make it easier for tumor cells to home on the pre-metastatic sites [79, 80] . Moreover, the extended C-terminal 'tail' domain of S100A9 which is unique among the S100 protein family and composed of 14 residues in the C-terminal ends of helix IV, is identical to the neutrophil immobilizing factor and has high sequence homology to the contact domain of high-molecular weight kininogen (HMWK or HK), suggesting that S100A9 may promote the localization of neutrophils and monocytes at the sites of inflammation [81] . A mutant of S100A9 was produced, truncated following amino acid 93 (designated 'tail-less' or TL-14), which eliminated the unusually long C-terminal 'tail' region from the protein.
Furthermore, it has been shown the interaction between S100A9 and EMMPRIN induced cdc42 activation which is known to promote filopodia formation, cell polarity, and migration. This could be the reason of EMMPRIN expression at the invasive conditions of cancer cells via EMMPRIN signal transduction [40, 46, 49] . S100A9 also acts as an antiinfection and anti-inflammation factor, although it is a Janusfaced molecule functioning which result in a potent amplifier of inflammation, cancer development and tumor spread [37] .
Binding affinity of protein to arachidonic acid and involved inflammation process S100A8/A9 heterodimer proteins can bind to polyunsaturated fatty acids such as oleic, linoleic, and arachidonic acid in a calcium-dependent manner. The arachidonic acid plays a major role in the immune response of neutrophils as a substrate for either cyclooxygenase (COX) or lipoxygenase (LOX) pathways in the generation of prostaglandins and leukoterines, respectively. S100A8/A9 could be involved in uptake and transport of arachidonic acid by fatty acid translocase/CD36 which leads to specific responses by regulating the delivery and synthesis of these pro-inflammatory compounds [82] . S100A8/A9 complex has been considered as an intermediate intracellular reservoir for arachidonic acid, so probably may perform an important regulatory role in accessibility of arachidonic acid and its metabolizing enzymes activities [83] . The strong evidence has confirmed that the unique C-tail of S100A9 containing 14 residues in the C-terminal ends of protein which involved three consecutive histidine residues (His103-His105) represents the site which the carboxy-group of fatty acid can bound to the S100A8/ A9 protein complex. This unique site within the C-tail of S100A9 has not been yet reported for other S100 proteins [84] . The S100A9 mutant proteins were investigated with protein-protein interaction methods and its functional properties in arachidonic acid-binding capacity were analyzed respectively. The result explained that substitution alter of either R85, H91, K93, H95, H103, H104, H105 and H106 by other residues induced a clear reduction of the arachidonic acid binding capacity of protein complex [85] .
NADPH oxidase activation of S100A8/A9 protein
Activate nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a membrane enzyme that is responsible for the production of variety of reactive oxygen species (ROS) or free radical molecules which leads to kill intracellular pathogens and microorganisms. The reports offer that overexpression of S100A8/A9 in activated cell lines leads to enhanced NADPH oxidase activity and reactive oxygen species (ROS) production,, including HOCl, H 2 O 2 , and NO [75] . The enhanced rates of ROS have been observed in almost all cancer types. The excessive ROS, can damage cellular compartment such as nucleus and then cell genome. Specially, the ROS-related oxidation of DNA is one of the main causes of mutations which could increase cancer risk and contribute to carcinogenesis. The oxidation of Cys41of S100A8 to cysteic acid may be stabilized by hydrogen bonding with amines on neighboring Lys residues. A novel inter-and intra-chain covalent cross-linking, between the thiol groups of Cys or Met residues and amine groups of Lys residues, such as sulfoxides, sulfenamide, sulfonamide, sulfonamide and S-nitrosylate (S-NO bonds) formation is also reported [86, 87] .
The role of S100A8/A9 in malignancy and tumor invasion
Tumor invasion and migration of cancer cells will be arising as a result of particular potential of tumor cells to invade the surrounding tissue, and to enter blood or lymphatic vessels. The non-neoplastic host cells of the tumor microenvironment, play key roles in promoting malignancy and DAMP molecules such as calprotectin have been increasingly regarded as a new candidate with important roles in modulating of host immune responses which leads to promote tumorigenesis and malignancy progression. in tumor cells, S100A8/A9 induce activation of NF-kB which enhances expression of genes, including Cxcl1, Ccl5 and Ccl7, Slc39a10, Lcn2, Zc3h12a, Enpp2 whose products are known in angiogenesis, tumor migration, wound healing, and formation of pre-metastatic niches into the surrounding tissue and organs [88, 89] . Recent studies on different types of cancer cells have shown that low extracellular concentrations of calprotectin promote migration of cancer cells and Knockdown of S100A8 and S100A9 expression decreases malignancy and tumor invasion [90, 91] . A study has shown that metastatic colonies were infiltrated by CD11b+ cells comprising granulocytes and monocytes/macrophages. As a result of the depletion of these CD11b+ cells it has been observed that colony growth markedly reduced. surveys show that S100A8, S100A9 and angiopoietin-like 7 (ANGPTL7) expressions were significantly reduced in the cancer cells by removing the CD11b+ cells. These led to inhibition of cancer growth, metastases and subcutaneous tumors [92] . Matrix metalloproteinases (MMPs) are known to play an important role in the tumor microenvironment during progression, migration and invasion by regulating a variety of physiological processes and signaling events. S100A8 and S100A9 knockdown in the cancer cells leads to reduction in MMP2 and MMP9 expression which suggests their regulation by calprotectin, and have an effect on decreasing tumor cell migration and invasion. It is already known that the expression of MMP10, MMP1, MMP2, and MMP9 in keratinocytes were increased at 24 h after S100A8/A9 treatment [92, 93] . Based on recent findings which suggest new insights in the role of S100A8/A9 protein in malignancy, the protein has completely different outcomes in malignancy and tumor invasion whether the source of the aforementioned protein is extracellular or intracellular. Intracellular expression of calprotectin reduce cancer invasiveness by promoting epithelial and adhesion characteristics of cancer cells through induction of expression of epithelial genes such as E-cadherin, Zona Occludens 1 (ZO-1), Integrin-α5 and pro-epithelial regulator (Pax5), suppression of mesenchymal genes like paxillin and slug expression and also decreased phosphorylation level of Focal Adhesion Kinase 1 (FAK1) and it's activity [94] . The isobaric tags for relative and absolute quantitation (iTRAQ) proteomic technique was used to analyze the differential expression of S100A8 proteins between fresh primary breast tumor (PBT) tissue and fresh paired metastatic lymph nodes (PMLN) tissue. The results showed that the S100-A8 up regulated 1.72-fold in PMLN tissue, compared to PBT tissue [89] .
Anti-tumor responses of S100A8/A9 by inducing apoptosis in various tumor cells
The extensive studies have been conducted the effects of extracellular S100A8/S100A9 protein or its monomers individually, S100A8 or S100A9, on various types of cancer cells which is summarized in Table 2 . The cytotoxic effects of extracellular S100A8/A9 have been observed on human cancer cell lines [9] . These studies strongly indicate that S100A8/A9 elicit powerful anti-tumor responses and induces cell death program or apoptosis which appears to be independent from RAGE or FADD-dependent death receptors [95, 96] . Cell treating with high concentration of S100A8/A9 caused caspase activation, specially the caspase which involved in the intrinsic or mitochondrial pathway. In result of calprotectin treatment, any significant increase in Caspase-8 activity were not been shown while increased activity in caspase-3/caspase-7 was significantly observed. Actually the cell death induced by S100A8/A9 is mediated by specific components of the intrinsic death pathway. For the purpose of quantitative investigation on the mitochondrial membrane integrity in presence of S100A8/A9, data revealed a rapid decrease in the mitochondrial membrane potential (ΔΨm) which represents the outer mitochondrial membrane (OMM) permeabilization. Recent studies reveal that increased permeabilization of outer mitochondrial membrane did not result in release of cytochrome c, apoptosisinducing factor (AIF) and endonuclease G (Endo G). On the other hand, both Smac/DIABLO and Omi/HtrA2 were selectively detected in cytoplasm which indicates its release into the cytoplasmic space. This concomitantly is followed by a reduced expression of Drp1, which inhibits mitochondrial fission machinery. Smac/DIABLO and Omi/HtrA2 are able to promote the phosphorylation of inhibitor of apoptosis (IAP) family such as XIAP (member of mammalian) and their cleavage. The outer mitochondrial membrane permeabilization is often controlled by BCL-2 family proteins which have either pro-or anti-apoptotic members and regulate the mitochondrial pathway of apoptosis. Treatment with S100A8/A9 also leads to low expression of the antiapoptotic proteins Bcl2 and Bcl-XL, whereas expression of the pro-apoptotic proteins such as Bax, Bad and BNIP3 was not changed. S100A8/A9 treatment did not induce the translocation of Bax in mitochondria but activated Bak homodimerization was observed by immune-blotting studies.
Together, these results indicate that S100A8/A9 induces the specific release of Smac/DIABLO and Omi/HtrA2 from mitochondria and disturbs the natural balance between proand anti-apoptotic proteins [96] . So the cytotoxic effects of S100A8/A9 heterodimer on cells and it's cell death inducing effects are in a time and concentration-dependent manner. Interestingly, it is determined that hS100A8/A9 heterodimer complex promoted cell apoptosis, whereas hS100A8 and hS100A9 individually indicate little inducing effect on apoptosis [97] .
Conclusions and future perspectives
Recent studies have shown the presence of S100A8 and S100A9 and 'excess' inflammatory secreted factors in the tumor microenvironment and it is evident that inflammation conditions have powerful effects on neoplastic process and cancer development. Under normal physiological conditions, the extracellular concentrations of calprotectin are extremely low but in inflammatory condition the active cells of immune system secret it continuously then they activate many downstream signaling pathways and divert inflammatory and cancer mechanisms such as: inflammatory factors producing, protein-protein interactions, MMP production, ECM remodeling which facilitate invasion, coating tumor cells to make available receptors for disseminating cells via lymphatic system and then metastasis and tumor spread. calprotectin is a native, not genotoxic, potent apoptosis-inducing factor against tumor cells which at high extracellular concentrations induces the cell death program or apoptosis pathway Table 2 The effects of S100A8/S100A9 protein complexes and its monomers individually, S100A8 or S100A9, on various human cancer cell lines Protein Cell lines Effects S100A8/S100A9 Periodontal ligament cells (PDLCs) [95] , human gingival fibroblasts (HGFs)t [1] , colon adenocarcinoma and carcinoma cell lines (SW742 and HT29/219) [9] , MCF7 (human, estrogen receptor positive breast cancer), MCF7-Bcl2 overexpressing, MDA-MB231 (human, estrogen receptor negative breast cancer), Jurkat (human T-cell leukemia), Jurkat-Bcl2 overexpressing, Jurkat FADD-DN BJAB (murine B cell leukemia), BJAB FADD-DN, L929
(murine fibrosarcoma), HEK-293 (human embryonic kidney), and SHEP and KELLY (human neuroblastomas) [96] , human prostate cancer cell (LNCaP) [98] Increased the activation of nuclear factor NF -kB (NF-kB) Stimulating the expression of pro-inflammatory cytokines IL-6, IL-8, TNFa, and COX2 Apoptosis-inducing activity S100A8 Periodontal ligament cells (PDLCs) [95] , human gingival fibroblasts (HGFs)t [1] , SK-MEL-2 (HTB-68), SK-MEL-3 (HTB-69), SK-MEL-5 (HTB-70), MeWo (HTB-65), and A2058 (CRL-11147) [46] S100A8 individually exerted little effect rather than S100A8/ S100A9 S100A9 Periodontal ligament cells (PDLCs) [95] , human gingival fibroblasts (HGFs) [1] , human melanoma (A-375) [99], SK-MEL-2 (HTB-68), SK-MEL-3 (HTB-69), SK-MEL-5 (HTB-70), MeWo (HTB-65), and A2058 (CRL-11147) [46] S100A9 individually exerted little effect rather than S100A8/ S100A9
in cancer cells so it can prevent cancer. Effective extracellular concentrations for promoting apoptosis of tumor cells shown by different studies are in the range of 20-250 µg/ml (approximately 1-10 µM), while at lower levels (< 20 µg/ ml) S100A8/A9 seem to promote proliferation of tumor cells [90] . On the other hand, at high intracellular concentrations, S100A8/A9 do not affect apoptosis pathway instead by regulating the epithelial-mesenchymal transition-the mesenchymal-epithelial transition (EMT-MET) signaling cascades, it induces a reduction in cancer cell invasion capacity. calprotectin can be considered as an intelligent molecule which its function depends on its concentration and location inside or outside the cell. However, the molecular mechanism of proand anti-tumor properties of calprotectin is still unknown but the aim of this study is considering the significant roles of calprotectin in both inflammation-induced-cancer and cancer-induced-inflammation which leads to design novel cancer therapeutics methods.
